reference/5256212

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/5256212

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial\|Research Support, N.I.H., Intramural\|Research Support, Non-U.S. Gov't
endingPage	3715
issn	1527-7755 0732-183X
issueIdentifier	33
pageRange	3705-3715
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	3705
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_266f09c09d1e3aa97cbfe9240f44f32b http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_448c3d7a8b95445db230c0de0b6d375a http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_969ccf6fe026f2f48265f62ea5c814c6
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_4c4f4a6c5972ec75e3fd979c7098e660 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f61934972826c8132b06bbc141f25782 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5e4651ddb1e2085b46c23e16f1148a9b http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d62f51386142d8e7576b9b70134d6e59 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_23ab24746a15a095ce9477e69e3b45b7 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_55f33abcc99d983e0438225ed9f44177 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_602877bffedd8359a1c88ec2623124f6 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_56fca6eadd6503e2daa050cc8528f23e
bibliographicCitation	Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20;32(33):3705–15. PMID: 25311217; PMCID: PMC4226804.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0351645f02c3911f842fd18b7d53ef72 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6490ad073cb5d4e222764c3b8cf7cd1d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b376b49c4930a6912237e7f1470f8866 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c99f6524efed74e0a21ef2d53965db9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0af11f3dc7a3b14d48e06372af05e759 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e6f0e2f2d6020e3f1b9889c0d753f0f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5f85d801dcf389a6acae1e1fc4af2c6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dbae2aebb832719240406a4728401800 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_93451090f00055fe5db696ad31769eab http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_564f5b65e03b6143ce2f1564b7da6192 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db794a676298b485d63905fed1491587 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d803c5374369c9f91d29e7d2278999e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c0b55b0c71dd688bd11e3b6f260b3c1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac8fd2118addd2d87b6c9980da7431c2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9a232cde3995707f29d6439162dbbbf7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_844bac08c22f4e3744bff1d56aa74739 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b18758072b5877e51b104c358da4f5fe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3088dac1a696393e5241fffc765b9b9a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d93cfa4d1ce7982a7060c74903b9687c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffa97457b70312fd04fbbe9745f6014d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_82303ad91bf2ffe5db82da5eaae91f24 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_608a705a43b9a24c70b0cde794410168 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bab0cef7effae18005cc174bad9aac46 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b041fc0737a87c428bdd990bd0c0e8f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd8db8942777911a6c960786c38575ca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0cd61cf5528ebe5b7a352bb8241b1c10 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_953cd3d852624df01e57dd89a13e6ab6
date	2014-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/25311217 https://pubmed.ncbi.nlm.nih.gov/PMC4226804 https://doi.org/10.1200/jco.2013.53.4578
isPartOf	https://portal.issn.org/resource/ISSN/1527-7755 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023 https://portal.issn.org/resource/ISSN/0732-183X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
discusses	http://id.nlm.nih.gov/mesh/M0026444 http://id.nlm.nih.gov/mesh/M0001103 http://id.nlm.nih.gov/mesh/M0001108 http://id.nlm.nih.gov/mesh/M0018556 http://id.nlm.nih.gov/mesh/M0021196 http://id.nlm.nih.gov/mesh/M0025473 http://id.nlm.nih.gov/mesh/M0562608 http://id.nlm.nih.gov/mesh/M0366130
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D020360 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D000726Q000627 http://id.nlm.nih.gov/mesh/D011471Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011468 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000069501 http://id.nlm.nih.gov/mesh/D016729Q000009 http://id.nlm.nih.gov/mesh/D011471Q000097 http://id.nlm.nih.gov/mesh/D013739Q000097 http://id.nlm.nih.gov/mesh/D017430Q000097 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D011944Q000032 http://id.nlm.nih.gov/mesh/D000730Q000008 http://id.nlm.nih.gov/mesh/D016729Q000008 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D011471Q000473
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5881 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10635 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9c2eb41267934654ad86d8795624a05b http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9821849 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID657180 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6013 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_005ef34c8ba989d84eb20cdc3a19dd7c http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID132971 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10251

Total number of triples: 100.